Combination lipid-lowering therapy with statins: Safety issues in the postcerivastatin era

Expert Opinion on Drug Safety

Volumn 2, Issue 3, 2003, Pages 269-286

  Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HMG CoA reductase inhibitors (statins); myopathy; myositis; pharmacokinetics; rhabdomyolysis; safety

Indexed keywords

CERIVASTATIN; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRIDINE DERIVATIVE;

BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; METABOLISM; MUSCLE DISEASE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MUSCULAR DISEASES; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDINES; RISK FACTORS;

EID: 0141483647     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.3.269     Document Type: Review

References (128)

1. SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623-1630. (Pubitemid 35379733)
2. NO AUTHORS LISTED: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
3. NO AUTHORS LISTED: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
4. NO AUTHORS LISTED: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339:1349-1357.
5. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622. (Pubitemid 28248586)
6. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001-1009. (Pubitemid 26338729)
7. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333:1301-1307.
8. NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
9. PASTERNAK RC, SMITH SC Jr, BAIREY-MERZ CN et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. (2002) 40:568-573.
10. JACOBSON TA, GRIFFITHS GG, VARAS C et al.: Impact of evidence-based 'clinical judgment' on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch. Intern. Med. (2000) 160:1361-1369. (Pubitemid 30252785)
11. FOOT DK, LEWIS RP, PEARSON TA et al.: Demographics and cardiology, 1950-2050. J. Am. Coll. Cardiol. (2000) 35:B66-B80.
12. JACOBSON TA: Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Curr. Atheroscler. Rep. (2001) 3:373-382.
13. DAVIDSON MH: Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cardiol. (2002) 90:K50-K60.
14. OMAR MA, WILSON JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. (2002) 36:288-295. (Pubitemid 34126824)
15. UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. (2000) 22:441-457. (Pubitemid 30386462)
16. GOLDMAN JA, FISHMAN AB, LEE JE et al.: The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum. (1989) 32:358-359. (Pubitemid 19100426)
17. WILLIAMS D, FEELY J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. (2002) 41:343-370. (Pubitemid 34713089)
18. HAMILTON-CRAIG I: Statin-associated myopathy. Med. J. Aust. (2001) 175:486-489. (Pubitemid 33039862)
19. PEDERSEN TR, BERG K, COOK TJ et al.: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. (1996) 156:2085-2092. (Pubitemid 26346967)
20. BAKER SK, TARNOPOLSKY MA: Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med. (2001) 24:258-272. (Pubitemid 33097304)
21. PHILLIPS PS, HAAS RH, BANNYKH S et al.: Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. (2002) 137:581-585.
22. OMAR MA, WILSON JP, COX TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. (2001) 35:1096-1107. (Pubitemid 32880030)
23. GROB D: Rhabdomyolysis and drug-related myopathies. Curr. Opin. Rheumatol. (1990) 2:908-915.
24. PRENDERGAST BD, GEORGE CF: Drug-induced rhabdomyolysis-mechanisms and management. Postgrad. Med. J. (1993) 69:333-336.
25. POELS PJ, GABREELS FJ: Rhabdomyolysis: a review of the literature. Clin. Neurol. Neurosurg. (1993) 95:175-192. (Pubitemid 23288234)
26. BERTOLINI S, BON GB, CAMPBELL LM et al.: Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis (1997) 130:191-197. (Pubitemid 27191040)
27. DART A, JERUMS G, NICHOLSON G et al.: A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. (1997) 80:39-44. (Pubitemid 27274576)
28. LAMBRECHT LJ, MALINI PL: Efficacy and tolerability of simvastatin 20 mg versus pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group. Acta Cardiol. (1993) 48:541-554. (Pubitemid 24048797)
29. FARMER JA, TORRE-AMIONE G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. (2000) 23:197-213.
30. SIMES J, FURBERG CD, BRAUNWALD E et al.: Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur. Heart J. (2002) 23:207-215. (Pubitemid 36358242)
31. DUJOVNE CA, CHREMOS AN, POOL JL et al.: Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am. J. Med. (1991) 91:S25-S30.
32. BLACK DM, BAKKER-ARKEMA RG, NAWROCKI JW: An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. (1998) 158:577-584. (Pubitemid 28144814)
33. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718. (Pubitemid 32259905)
34. JOKUBAITIS LA: Updated clinical safety experience with fluvastatin. Am. J. Cardiol. (1994) 73:D18-D24. (Pubitemid 124007815)
35. SERRUYS PW, DE FAYER P, MACAYA C et al. for the Lescol Intervention Prevention Study Investigators: fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA (2002) 256:3215-3222. (Pubitemid 34686102)
36. STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346:539-540. Letter.
37. CORSINI A, BELLOSTA S, BAETTA R et al.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84:413-428.
38. LANE RJ, MASTAGLIA FL: Drug-induced myopathies in man. Lancet (1978) 2:562-566.
39. FICHTL B, KURZ H: Binding of drugs to human muscle. Eur. J. Clin. Pharmacol. (1978) 14:335-340. (Pubitemid 9098877)
40. LANG JE, WANG P, GLUECK CJ: Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin. Chim. Acta (1996) 254:65-92.
41. HINO I, AKAMA H, FURUYA T et al.: Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum. (1996) 39:1259-1260. (Pubitemid 26240245)
42. BERTZ RJ, GRANNEMAN GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. (1997) 32:210-258. (Pubitemid 27122521)
43. WRIGHTON SA, VANDENBRANDEN M, RING BJ: The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. (1996) 24:461-473. (Pubitemid 27156932)
44. HERMAN RJ: Drug interactions and the statins. CMAJ (1999) 161:1281-1286.
45. SHIMADA T, YAMAZAKI H, MIMURA M et al.: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414-423. (Pubitemid 24229655)
46. THUMMEL KE, SHEN DD, PODOLLTD et al.: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. (1994) 271:557-566. (Pubitemid 24333174)
47. MIETTINEN TA, GYLLING H, STRANDBERG T et al.: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. Br. Med. J. (1998) 316:1127-1130. (Pubitemid 28156458)
48. REINOSO RF, SANCHEZ NA, GARCIA MJ et al.: Pharmacokinetic interactions of statins. Methods Find. Exp. Clin. Pharmacol. (2001) 23:541-566. (Pubitemid 34229358)
49. MILLER DB, SPENCE JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. (1998) 34:155-162. (Pubitemid 28077673)
50. SHEK A, FERRILL MJ: Statin-fibrate combination therapy. Ann. Pharmacother. (2001) 35:908-917. (Pubitemid 32678717)
51. WEN X, WANG JS, BACKMAN JT et al.: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. (2001) 29:1359-1361. (Pubitemid 33000680)
52. PRUEKSARITANONT T, ZHAO JJ, MA B et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. (2002) 301:1042-1051. (Pubitemid 34595097)
53. PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. (2002) 30:505-512. (Pubitemid 34456970)
54. EVANS M, REES A: The myotoxicity of statins. Curr. Opin. Lipidol. (2002) 13:415-420. (Pubitemid 34831945)
55. MU YM, YANASE T, NISHI Y et al.: Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol. Cell Endocrinol. (2001) 181:239-248. (Pubitemid 32703765)
56. KATSILAMBROS N, BRAATEN J, FERGUSON BD et al.: Muscular syndrome after clofibrate. N. Engl. J. Med. (1972) 286:1110-1111.
57. SEKOWSKI I, SAMUEL P: Clofibrate-induced acute muscular syndrome. Am. J. Cardiol. (1972) 30:572-574.
58. AAKHUS S, DAHL K, WIDEROE TE: Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol. Dial. Transplant. (1999) 14:648-654. (Pubitemid 29105993)
59. BRUNNER FP, FASSBINDER W, BROYER M et al.: Survival on renal replacement therapy: data from the EDTA Registry. Nephrol. Dial. Transplant. (1988) 3:109-122.
60. KLINTMALM GB, IWATSUKI S, STARZL TE: Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation (1981) 32:488-489. (Pubitemid 12204706)
61. NO AUTHORS LISTED: Sandimmune® (cyclosporine). Novartis US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2388-2391.
62. AKHLAGHI F, MCLACHLAN AJ, KEOGH AM et al.: Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br. J. Clin. Pharmacol. (1997) 44:537-542. (Pubitemid 27517479)
63. DUGGAN DE, VICKERS S: Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev. (1990) 22:333-362. (Pubitemid 20340903)
64. TOBERT JA: Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. (1988) 62:J28-J34.
65. REAVEN P, WITZTUM JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann. Intern. Med. (1988) 109:597-598.
66. GUPTA EK, ITO MK: Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. (2002) 4:124-137. (Pubitemid 34408630)
67. OLBRICHT C, WANNER C, EISENHAUER T et al.: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. (1997) 62:311-321. (Pubitemid 27417797)
68. EAST C, ALIVIZATOS PA, GRUNDY SM et al.: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med. (1988) 318:47-48. (Pubitemid 18025478)
69. GULLESTAD L, NORDAL KP, BERG KJ et al.: Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant. Proc. (1999) 31:2163-2165. (Pubitemid 29376559)
70. KYRKLUND C, BACKMAN JT, KIVISTO KT et al.: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. (2001) 69:340-345. (Pubitemid 32477075)
71. KIVISTO KT, KANTOLA T, NEUVONEN PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. (1998) 46:49-53. (Pubitemid 28308424)
72. GRUNDEN JW, FISHER KA: Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann. Pharmacother. (1997) 31:859-863. (Pubitemid 27332475)
73. HORN M: Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch. Dermatol. (1996) 132:1254. (Pubitemid 26343986)
74. NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. (1996) 60:54-61. (Pubitemid 26279221)
75. LEES RS, LEES AM: Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N. Engl. J. Med. (1995) 333:664-665.
76. AYANIAN JZ, FUCHS CS, STONE RM: Lovastatin and rhabdomyolysis. Ann. Intern. Med. (1988) 109:682-683.
77. AZIE NE, BRATER DC, BECKER PA et al.: The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. (1998) 64:369-377. (Pubitemid 28473762)
78. BALLANTYNE CM, RADOVANCEVIC B, FARMER JA et al.: Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J. Am. Coll. Cardiol. (1992) 19:1315-1321.
79. KANDUS A, KOVAC D, KOSELJ M et al.: Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. Transplant. Proc. (1994) 26:2642-2643. (Pubitemid 24329262)
80. TRAINDL O, READING S, FRANZ M et al.: Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A. Transplant. Proc. (1992) 24:2745-2747. (Pubitemid 23011672)
81. KOBASHIGAWA JA, MURPHY FL, STEVENSON LW et al.: Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation (1990) 82:IV281-IV283.
82. NO AUTHORS LISTED: Mevacor® (lovastatin). Merck US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2132-2136.
83. GRUER PJ, VEGA JM, MERCURI MF et al.: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. (1999) 84:811-815. (Pubitemid 29469791)
84. ARNADOTTIR M, ERIKSSON LO, THYSELL H et al.: Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron (1993) 65:410-413. (Pubitemid 23321239)
85. KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64:177-182. (Pubitemid 28423853)
86. GILAD R, LAMPL Y: Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin. Neuropharmacol. (1999) 22:295-297. (Pubitemid 29506401)
87. MOGYOROSI A, BRADLEY B, SHOWALTER A et al.: Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J. Intern. Med. (1999) 246:599-602. (Pubitemid 30003182)
88. NO AUTHORS LISTED: Zocor® (simvastatin). Merck US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2219-2223.
89. ORLOFF DG: Supplemental NDA 19-766/S-051 (May 6, 2002 correspondence with Merck & Co., Inc.).
90. NO AUTHORS LISTED: Lipitor® (atorvastatin calcium). Pfizer US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2696-2700.
91. POSVAR EL, RADULOVIC LL, CILLA DD Jr et al.: Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J. Clin. Pharmacol. (1996) 36:728-731. (Pubitemid 26295777)
92. MALTZ HC, BALOG DL, CHEIGH JS: Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother. (1999) 33:1176-1179.
93. WENISCH C, KRAUSE R, FLADERER P et al.: Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am. J. Med. (2000) 109:78. (Pubitemid 30608752)
94. SIEDLIK PH, OLSON SC, YANG BB et al.: Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol. (1999) 39:501-504. (Pubitemid 29356471)
95. KANTOLA T, KIVISTO KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. (1998) 64:58-65. (Pubitemid 28377331)
96. MURDOCK DK, MURDOCK AK, MURDOCK RW et al.: Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am. Heart J. (1999) 138:151-155. (Pubitemid 29331136)
97. HENRY K, MELROE H, HUEBESCH J et al.: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet (1998) 352:1031-1032. (Pubitemid 28438577)
98. DUELL PB, CONNOR WE, ILLINGWORTH DR: Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol. (1998) 81:368-369. (Pubitemid 28099321)
99. VAN JT, PAN J, WASTY T et al.: Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. Cardiol. (2002) 89:1306-1308. (Pubitemid 34606896)
100. TARASENKO LC: August 13, 2002 correspondence from Pfizer, Inc., US Medical Information.
101. BOYD RA, STERN RH, STEWART BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P- glycoproteinmediated secretion. J. Clin. Pharmacol. (2000) 40:91-98.
102. CLARKE TA, WASKELL LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. (2003) 31:53-59. (Pubitemid 36735258)
103. LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107:32-37. (Pubitemid 36070929)
104. WHITE CM: A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. (2002) 42:963-970. (Pubitemid 34920793)
105. HSIANG B, ZHU Y, WANG Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. (1999) 274:37161-37168.
106. QUION JA, JONES PH: Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. (1994) 27:94-103.
107. NO AUTHORS LISTED: Pravachol® (pravastatin sodium). Bristol-Myers Squibb US prescribing information In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):1099-1103.
108. REGAZZI MB, IACONA I, CAMPANA C et al.: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant. Proc. (1993) 25:2732-2734. (Pubitemid 23239614)
109. PARK JW, SIEKMEIER R, MERZ M et al.: Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int. J. Clin. Pharmacol. Ther. (2002) 40:439-450.
110. YOSHIMURA N, OKA T, OKAMOTO M et al.: The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation (1992) 53:94-99.
111. ALDERMAN CP: Possible interaction between nefazodone and pravastatin. Ann. Pharmacother. (1999) 33:871.
112. NO AUTHORS LISTED: Lescol® (fluvastatin sodium). Novartis US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2361-2365.
113. FISCHER V, JOHANSON L, HEITZ F et al.: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos. (1999) 27:410-416. (Pubitemid 29114251)
114. JACOBSON TA, AMOROSA LF: Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am. J. Cardiol. (1994) 73:D25-D29. (Pubitemid 124007816)
115. PAUCIULLO P, BORGNINO C, PAOLETTI R et al.: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis (2000) 150:429-436. (Pubitemid 30336556)
116. FARNIER M, DEJAGER S: Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am. J. Cardiol. (2000) 85:53-57. (Pubitemid 30045545)
117. PAPADAKIS JA, GANOTAKIS ES, JAGROOP IA et al.: Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int. J. Cardiol. (1999) 69:237-244. (Pubitemid 29254099)
118. SPENCE JD, MUNOZ CE, HENDRICKS L et al.: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. (1995) 76:A80-A83.
119. SMIT JW, JANSEN GH, DE BRUIN TW et al.: Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am. J. Cardiol. (1995) 76:A126-A128.
120. ELIAV O, SCHURR D, PFISTER P et al.: High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am. J. Cardiol. (1995) 76:A76-A79.
121. LEITERSDORF E, MURATTI EN, ELIAV O et al.: Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am. J. Cardiol. (1995) 76:A84-A88.
122. LEITERSDORF E, MURATTI EN, ELIAV O et al.: Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am. J. Med. (1994) 96:401-407.
123. JARDINE A, HOLDAAS H: Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J. Clin. Pharm. Ther. (1999) 24:397-408. (Pubitemid 30064101)
124. FARNIER M, BARTOLINI M, SALKO T et al.: Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates. Am. J. Cardiol. (2003). In Press.
125. BAYS HE, DUJOVNE CA: Drug interactions of lipid-altering drugs. Drug Saf. (1998) 19:355-371. (Pubitemid 28505194)
126. GOLDBERG R, ROTH D: Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation (1996) 62:1559-1564. (Pubitemid 27009910)
127. HOLDAAS H et al.: The use of statins after solid organ transplantation. J. Nephrol. Dial. Tranplant. (2002) 17(8):1537.
128. NO AUTHORS LISTED: Choice of lipid-regulating drugs. Med. Lett. Drugs Ther. (2001) 43:43-48.